Stock Events

Stock Events

Oncolytics Biotech 

$0.8017
108
-$0.03-3.53% Thursday 20:00
-$0.02-2.08%Thursday 23:33After hours

Statistics

Day High
0.81
Day Low
0.801
52W High
1.51
52W Low
0.73
Volume
16,893
Avg. Volume
-
Mkt Cap
95.69M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.1
-0.08
-0.06
-0.04
Expected EPS
-0.0555654022
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-20.62MNet Income

Analyst Ratings

5.00Average Price Target
The highest estimate is 5.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ONCY. It's not an investment recommendation.
Amazon
14
AMZN
NVIDIA
14
NVDA
AMD
14
AMD
Microsoft
13
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is involved in developing oncology treatments, including oncolytic virus therapies, directly competing with Oncolytics Biotech's approach to cancer treatment.
Merck
MRK
Mkt Cap335.14B
Merck's extensive portfolio in oncology, including immunotherapy treatments, positions it as a competitor in the cancer treatment space, overlapping with Oncolytics Biotech's market.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb offers a range of cancer treatments, including immunotherapies that compete with Oncolytics Biotech's viral-based cancer therapies.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, with its focus on oncology and viral treatments, competes in the same space as Oncolytics Biotech, especially in the development of innovative cancer therapies.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a broad oncology division, including the development of treatments that could compete with Oncolytics Biotech's oncolytic virus therapy approach.
Novavax
NVAX
Mkt Cap1.33B
Novavax, while primarily known for vaccines, is exploring cancer vaccine treatments that could potentially compete with Oncolytics Biotech's viral-based therapies.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical division Janssen, develops a variety of oncology treatments that could compete with Oncolytics Biotech's approach to cancer therapy.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals focuses on developing monoclonal antibodies for cancer treatment, a method that could be seen as complementary or competitive to Oncolytics Biotech's viral therapies.
Sorrento Therapeutics
SRNE
Mkt Cap385,896
Sorrento Therapeutics is involved in the development of new therapies for cancer, including approaches that could compete with or complement Oncolytics Biotech's oncolytic virus strategy.
Vir Biotechnology
VIR
Mkt Cap1.56B
Vir Biotechnology, while focusing on infectious diseases, is exploring the potential of using viral vectors for therapeutic purposes, which could intersect with Oncolytics Biotech's cancer treatment strategies.

About

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
Show more...
CEO
Jared Kelly
Employees
29
Country
United States
ISIN
US68237V1035

Listings

MU
DE
ONYN.MU
STU
DE
ONYN.STU
BOATS
BOATS
ONCY.BOATS
XNAS
US
ONCY

1 Comments

toosie

one of my best investments

11
Rambo

And one my worst, keeps going down for the last year. Dropped over $105 in 6 months.

1
Me Medesimo

If you don't mention the percentage, it's a comment from a stock market newbie.

3
Rambo

31%. Happy now?

5

FAQ

What is Oncolytics Biotech stock price today?▼
The current price of ONCY is $0.80 USD — it has decreased by -3.53% in the past 24 hours. Watch Oncolytics Biotech stock price performance more closely on the chart.
What is Oncolytics Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Oncolytics Biotech stocks are traded under the ticker ONCY.
Is Oncolytics Biotech stock price growing?▼
ONCY stock has fallen by -3.87% compared to the previous week, the month change is a -6.62% fall, over the last year Oncolytics Biotech has showed a -20.62% decrease.
What is Oncolytics Biotech market cap?▼
Today Oncolytics Biotech has the market capitalization of 95.69M
When is the next Oncolytics Biotech earnings date?▼
Oncolytics Biotech is going to release the next earnings report on October 30, 2026.
What were Oncolytics Biotech earnings last quarter?▼
ONCY earnings for the last quarter are -0.08 USD per share, whereas the estimation was -0.05 USD resulting in a -45.76% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Oncolytics Biotech revenue for the last year?▼
Oncolytics Biotech revenue for the last year amounts to 0 USD.
What is Oncolytics Biotech net income for the last year?▼
ONCY net income for the last year is -20.62M USD.
How many employees does Oncolytics Biotech have?▼
As of August 21, 2026, the company has 29 employees.
In which sector is Oncolytics Biotech located?▼
Oncolytics Biotech operates in the Health & Wellness sector.
When did Oncolytics Biotech complete a stock split?▼
The last stock split for Oncolytics Biotech was on May 25, 2018 with a ratio of 1:9.5.
Where is Oncolytics Biotech headquartered?▼
Oncolytics Biotech is headquartered in SAN DIEGO, United States.